Loading
Obesity / Overweight / Chronic Weight Management · Phase 3 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 registration for a global, randomized controlled trial of ASC30 versus placebo for weight management in adults with obesity or overweight. No efficacy or safety results are currently posted in this registry record; the study is actively recruiting and outcome data are not yet available.
Phase 3, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Obesity, Overweight, Chronic Weight Management; age from 18 Years. Intervention: ASC30 Cohort 1; ASC30 Cohort 2; ASC30 Cohort 3. Compared with: Placebo Cohort 4 — Placebo Comparator. n = 3,003. 120 sites across 7 countries.
This is a Phase 3 registration for a global, randomized controlled trial of ASC30 versus placebo for weight management in adults with obesity or overweight. No efficacy or safety results are currently posted in this registry record; the study is actively recruiting and outcome data are not yet available.
No results are reported in this registry record; efficacy, safety, and tolerability outcomes are not yet available
The source did not state who this applies to in practice.
This is a clinical trial registry record with no reported results; the study is actively recruiting and outcomes have not yet been analysed or posted.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07743463). This is a study registration, not published results. Lead sponsor: Ascletis Pharma (China) Co., Limited. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 3003 participants (ESTIMATED). Conditions: Obesity, Overweight, Chronic Weight Management. Interventions: DRUG: ASC30 tablets A1; DRUG: Placebo. Primary outcome measures: Percent change in body weight from baseline to Week 72 , Baseline to Week 72. Brief summary: Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without T2DM.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.